

What is claimed is:

1. A method of treating a condition associated with elevated IL-18, comprising administering to a subject in need thereof an effective amount of an anti-IL-18 antibody wherein the anti-IL-18 antibody comprises:
 - (a) a HCDR1 having an amino acid sequence of SEQ ID NO: 122;
 - (b) a HCDR2 having an amino acid sequence of SEQ ID NO: 123;
 - (c) a HCDR3 having an amino acid sequence of SEQ ID NO: 124;
 - (d) a LCDR1 having an amino acid sequence of SEQ ID NO: 126;
 - (e) a LCDR2 having an amino acid sequence of SEQ ID NO: 127; and
 - (f) a LCDR3 having an amino acid sequence of SEQ ID NO: 128and, optionally wherein the condition associated with elevated IL-18 comprises any one or more of:
 - (a) inflammation, optionally wherein the inflammation is hyperinflammation;
 - (b) immune dysregulation that leads to multisystem organ failure;
 - (c) acute lung injury (ALI), optionally wherein the ALI is associated with a bacterial or viral infection, including coronavirus infection;
 - (d) acute respiratory distress syndrome (ARDS), optionally wherein the ARDS is associated with a bacterial or viral infection, including coronavirus infection;
 - (e) hemophagocytic lymphohistiocytosis (HLH), optionally where the HLH is associated with a bacterial or viral infection, including coronavirus infection;
 - (f) macrophage activation syndrome (MAS), optionally where the MAS is associated with a bacterial or viral infection, including coronavirus infection;
 - (g) cytokine storm that drives tissue injury and vascular permeability;
 - (h) post-infection pulmonary fibrosis;
 - (i) syndromes caused by NLRP3 overactivation/dysregulation due to viral infection; and
 - (j) pneumonia, optionally wherein the pneumonia is associated with a bacterial or viral infection, including coronavirus infection, thereby treating the condition.

2. The method of claim 1, wherein the method further comprises the following steps prior to administering the anti-IL-18 antibody:
 - (a) contacting a biological sample isolated from the subject with an anti-IL-18 antibody;
 - 5 (b) incubating the biological sample to allow an anti-IL-18 antibody to bind to IL-18; and
 - (c) detecting the presence of complexes formed between an anti-IL-18 antibody and IL-18 in the biological sample.
- 10 3. The method of claim 2, wherein the detection of IL-18 indicates that treatment of the condition associated with elevated IL-18 with an anti-IL-18 antibody will be effective.
4. A method of treating COVID-19 infection comprising administering an anti-IL-18 antibody to a subject in need thereof.
5. A method of treating severe COVID-19 pneumonia comprising administering an
15 anti-IL-18 antibody to a subject in need thereof.
6. A method of treating acute inflammatory disease, optionally associated with COVID-19, comprising administering an anti-IL-18 antibody to a subject in need thereof.
7. A method of treating respiratory failure associated with COVID-19 comprising
20 administering an anti-IL-18 antibody to a subject in need thereof.
8. A method of treating cytokine storm comprising administering an anti-IL-18 antibody to a subject in need thereof.
9. A method of treating Acute Respiratory Distress Syndrome (ARDS), optionally associated with COVID-19, comprising administering an anti-IL-18 antibody to a
25 subject in need thereof.
10. A method of treating hemophagocytic lymphohistiocytosis (HLH), optionally associated with COVID-19, comprising administering an anti-IL-18 antibody to a subject in need thereof.
11. A method of treating macrophage activation syndrome (MAS), optionally
30 associated with COVID-19, comprising administering an anti-IL-18 antibody to a subject in need thereof.
12. A method of preventing progression to ARDS in a subject, comprising administering an anti-IL-18 antibody to the subject not yet having ARDS and having a condition associated with elevated IL-18.

13. A method of preventing the need for ventilation/intubation of a subject, comprising administering an anti-IL-18 antibody to the subject not yet intubated/ventilated and having a condition associated with elevated IL-18.
14. The method of any one of claims 4-13, wherein the anti-IL-18 antibody comprises:
- (a) a HCDR1 having an amino acid sequence of SEQ ID NO: 122;
 - (b) a HCDR2 having an amino acid sequence of SEQ ID NO: 123;
 - (c) a HCDR3 having an amino acid sequence of SEQ ID NO: 124;
 - (d) a LCDR1 having an amino acid sequence of SEQ ID NO: 126;
 - (e) a LCDR2 having an amino acid sequence of SEQ ID NO: 127; and
 - (f) a LCDR3 having an amino acid sequence of SEQ ID NO: 128.
15. The method of any one of the preceding claims, wherein the anti-IL-18 antibody comprises a VH domain having an amino acid sequence that is at least 90% identical to the full sequence of SEQ ID NO: 121.
16. The method of any one of the preceding claims, wherein the anti-IL-18 antibody comprises a VH domain having an amino acid sequence that is identical to the full sequence of SEQ ID NO: 121.
17. The method of any one of the preceding claims, wherein the anti-IL-18 antibody comprises a VL domain having an amino acid sequence that is at least 90% identical to the full sequence of SEQ ID NO: 125.
18. The method of any one of the preceding claims, wherein the anti-IL-18 antibody comprises a VL domain having an amino acid sequence that is identical to the full sequence of SEQ ID NO: 125.
19. The method of any one of the preceding claims, wherein the anti-IL-18 antibody comprises an antibody VH domain and an antibody VL domain, wherein the amino acid sequence of the antibody VH domain and the antibody VL domain are at least 90% identical to the full sequence of SEQ ID NOS: 121 and 125.
20. The method of any one of claims 1-3 or 15-19, wherein the condition associated with elevated IL-18 is secondary hemophagocytic lymphohistiocytosis (sHLH).
21. The method of any one of claims 1-3, wherein the condition associated with elevated IL-18 is a COVID-19 infection.
22. The method of claim 20, wherein the hemophagocytic lymphohistiocytosis (HLH) is secondary hemophagocytic lymphohistiocytosis (sHLH).

23. The method of any of the preceding claims, wherein the anti-IL-18 antibody administered to the subject suppresses T cell activation.
24. The method of any of the preceding claims, wherein the anti-IL-18 antibody administered to the subject suppresses increased expression of cytokines.
- 5 25. The method of claim 24, wherein the anti-IL-18 antibody administered to the subject suppresses increased expression of IFN- γ .
26. The method of any of the preceding claims, wherein the anti-IL-18 antibody administered to the subject reduces the subject's risk of mortality or morbidity.
27. The method of any one of the preceding claims, wherein the subject is human.
- 10 28. The method of any one of claims 1-3 or 15-19, wherein the subject has a respiratory disease, optionally caused by a coronavirus infection.
29. The method of any one of claims 1-3 or 15-19, wherein the subject has pneumonia.
30. The method of any one of claims 1-3 or 15-19, wherein the subject has acute lung injury (ALI).
- 15 31. The method of any one of claims 1-3 or 15-19, wherein the subject has acute respiratory distress syndrome (ARDS).
32. The method of any one of claims 1-3 or 15-19, wherein the subject has a mild coronavirus infection.
- 20 33. The method of any one of claims 1-3 or 15-19, wherein the subject has a moderate coronavirus infection.
34. The method of any one of claims 1-3 or 15-19, wherein the subject has a severe coronavirus infection.
- 25 35. The method of any one of claims 1-3 or 15-19, wherein the subject is at the Early Infection (Stage I) of a coronavirus infection.
36. The method of any one of claims 1-3 or 15-19, wherein the subject is at the Pulmonary Phase (Stage II) of a coronavirus infection.
37. The method of any one of claims 1-3 or 15-19, wherein the subject is at the Hyperinflammation Phase (Stage III) of a coronavirus infection.
- 30 38. The method of any one of the preceding claims, wherein the subject is a pediatric subject.
39. The method of any one of the preceding claims, wherein the subject is an adult.
40. A kit for use in a method of any one of the preceding claims comprising an anti-IL-18 antibody and reagents for carrying out the method.